This randomized clinical trial examines data via prespecified analysis to evaluate the bleeding risk of the novel factor XI inhibitor abelacimab vs rivaroxaban in patients with atrial fibrillation (AF) according to their age (<75 vs ≥75 years).
This randomized clinical trial examines data via prespecified analysis to evaluate the bleeding risk of the novel factor XI inhibitor abelacimab vs rivaroxaban in patients with atrial fibrillation (AF) according to their age (<75 vs ≥75 years).